Non-profit website: free to use. No fees from patients, hospitals or doctors. Not an agency. · Free · Not an agencyAbout this site
Radiation oncology · Fudan University Shanghai Cancer Center · Shanghai

Dr. Kong Lin孔琳

Chief Physician

Summary compiled from public information, updated 18 Nov 2026. It has not been checked against the hospital website yet. Confirm details with the hospital before you travel.

Dr. Kong Lin

Professional overview

Dr. Kong Lin is a Chief Physician and Doctoral Supervisor at the Radiotherapy Center of Fudan University Shanghai Cancer Center, specializing in radiotherapy and comprehensive treatment for head and neck and central nervous system tumors.

SpecialtyRadiation oncology
Clinical titleChief Physician
Academic rolesDoctoral Supervisor
DepartmentRadiotherapy Center
HospitalFudan University Shanghai Cancer Center
CityShanghai
Hospital roleHead of the Head and Neck and Central Nervous System Tumor Department, Shanghai Proton and Heavy Ion Center / Fudan University Shanghai Cancer Center

Areas of focus

Nasopharyngeal carcinomaTreatment with conventional photon intensity-modulated radiotherapy, proton and heavy ion radiotherapy, and comprehensive therapy
Head and neck cancersIncluding nasal cavity and paranasal sinus cancer, oral/oropharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, and salivary gland tumors
Central nervous system tumorsIncluding meningioma, glioma, chordoma, adenoid cystic carcinoma, mucosal malignant melanoma of the head and neck, and olfactory neuroblastoma
Ocular tumorsTreatment with proton and heavy ion radiotherapy

Background

  • 1997Began clinical and research work in radiotherapy and comprehensive treatment for nasopharyngeal carcinoma and other head and neck and central nervous system tumors at the Department of Radiation Oncology, Fudan University Shanghai Cancer Center
  • 2007Conducted two prospective clinical trials on induction chemotherapy with TPF regimen followed by conformal intensity-modulated radiotherapy plus concurrent chemotherapy for locally advanced nasopharyngeal carcinoma
  • 2008Authored the chapter 'Second Primary Tumors' in the Encyclopedia of Cancer (Springer)
  • 2012Conducted a phase III randomized controlled trial using nimotuzumab instead of cisplatin as a radiosensitizer during radiotherapy for locally advanced nasopharyngeal carcinoma

Experience & recognition

  • Recipient of the Shanghai Anti-Cancer Association Science and Technology Award (Third Prize, 2019)
  • Recipient of the Shanghai Anti-Cancer Association Science and Technology Award (Third Prize, 2020)
  • Recipient of the Shanghai Anti-Cancer Association Science and Technology Award (First Prize, 2021)
  • Recipient of the Michael Goitein Award from PTCOG (2023)

Professional roles

  • Chair, Proton and Heavy Ion Radiotherapy Committee, China International Exchange and Promotive Association for Medical and Health Care (CPAM)
  • Vice Chair, Particle Radiotherapy Committee, China Anti-Cancer Association (CACA)
  • Standing Committee Member, Precision Oncology Committee, China Anti-Cancer Association (CACA)
  • Standing Committee Member, Oral and Maxillofacial Tumor Integration Committee, China Anti-Cancer Association (CACA)
  • Member, Nasopharyngeal Carcinoma Integration Committee, China Anti-Cancer Association (CACA)
  • Standing Committee Member, Nasopharyngeal Carcinoma Prevention and Treatment Branch, China International Exchange and Promotive Association for Medical and Health Care (CPAM)
  • Member, Glioma Committee, Chinese Medical Doctor Association (CMDA)
  • Member, Neuro-Oncology Expert Committee, Chinese Society of Clinical Oncology (CSCO)

Frequently asked questions

What does Dr. Kong Lin specialize in?

Specializes in conventional photon intensity-modulated radiotherapy, proton and heavy ion radiotherapy, and comprehensive treatment for nasopharyngeal carcinoma, nasal cavity and paranasal sinus cancer, oral/oropharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, salivary gland tumors, ocular tumors, meningioma, glioma, chordoma, adenoid cystic carcinoma, head and neck mucosal malignant melanoma, and olfactory neuroblastoma.

Which hospital and department is Dr. Kong Lin in?

At the Radiotherapy Center of Fudan University Shanghai Cancer Center

Sources

Dr. Kong Lin has not reviewed this page.